Ing. Daniel Buša

Research specialist, Department of Internal Medicine, Hematology and Oncology

Correspondence Address:
Jihlavská 340/20, 625 00 Brno

Office: bldg. F01B2/156
Kamenice 126/3
625 00 Brno

Show on the map

Phone:	+420 549 49 5437
E‑mail:

social and academic networks:

Basic information

Type

Total number of publications: 11

2023

Acute myeloid leukemia suppression by palbociclib and ponatinib in patient-derived xenograft.

BUŠA Daniel ČULEN Martin LOJA Tomáš JEŽÍŠKOVÁ Ivana FOLTA Alois MAYER Jiří

Conference abstract

Year: 2023, type: Conference abstract
AML engraftment in humanized ossicles is not governed by biomaterial selection.

ČULEN Martin BUŠA Daniel HERUDKOVÁ Zdeňka HÝL Jan VLAŽNÝ Jakub MATULOVÁ Květoslava REPKO Martin VOJTOVÁ Lucy MAYER Jiří

Conference abstract

Year: 2023, type: Conference abstract
Biomaterial selection does not affect AML engraftment in humanized ossicles.

ČULEN Martin LOJA Tomáš BUŠA Daniel HERUDKOVÁ Zdeňka HÝL Jan VLAŽNÝ Jakub LIŠKOVÁ K. REPKO Martin VOJTOVÁ Lucy MAYER Jiří

Conference abstract

Year: 2023, type: Conference abstract
Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing.

LADUNGOVÁ Adriana BUŠA Daniel LODHI Yusuf HÝL Jan ČULEN Martin ŠMÍDA Michal

Conference abstract

Year: 2023, type: Conference abstract
Inhibition of acute myeloid leukemia using palbociclib and ponatinib in a patient-derived xenograft model.

BUŠA Daniel ČULEN Martin LOJA Tomáš JEŽÍŠKOVÁ Ivana FOLTA Adam MAYER Jiří

Conference abstract

Year: 2023, type: Conference abstract

2022

. Drug repurposing for venetoclax-resistant acute myeloid leukemia.

LADUNGOVÁ Adriana BUŠA Daniel LODHI Yusuf HÝL Jan ČULEN Martin ŠMÍDA Michal

Conference abstract

Year: 2022, type: Conference abstract
Genome-wide Screening Optimizations and High-throughput Compound Screening to Identify Novel Treatment Options in Venetoclax-resistant AML

LODHI Yusuf LADUNGOVÁ Adriana BUŠA Daniel PESCHELOVÁ Helena ČULEN Martin ŠMÍDA Michal

Conference abstract

Year: 2022, type: Conference abstract
Prediction of novel treatment options for CLL and AML cells based on drug repurposing.

LADUNGOVÁ Adriana BUŠA Daniel PESCHELOVÁ Helena LODHI Yusuf ČULEN Martin ŠMÍDA Michal

Conference abstract

Year: 2022, type: Conference abstract
Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing.

LADUNGOVÁ Adriana BUŠA Daniel LODHI Yusuf HÝL Jan ČULEN Martin ŠMÍDA Michal

Conference abstract

Year: 2022, type: Conference abstract

2021

Acute myeloid leukemia regression induced by palbociclib and ponatinib in patient –derived xenograft model.

BUŠA Daniel LOJA Tomáš JEŽÍŠKOVÁ Ivana FOLTA A. MAYER Jiří ČULEN Martin

Conference abstract

Year: 2021, type: Conference abstract